IMWG consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma
CAR T-cell therapy represents an innovative approach for patients with advanced, treatment-resistant multiple myeloma, showing promising response rates between 73% and 98%. Currently, three CAR T-cell products have received approval in different regions: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are approved in the United States, Europe, Canada (ide-cel only), and Brazil (cilta-cel only), while equecabtagene autoleucel (eque-cel) has been approved in China.
CAR T-cell therapy differs significantly from traditional myeloma treatments, with unique side effects that demand specialised management strategies. To address these, the International Myeloma Working Group convened a panel of experts in haematopoietic cell transplantation, cell therapy, and myeloma care to establish guidelines for clinical use. Their consensus opinion provides essential insights to support healthcare professionals in safely and effectively implementing CAR T-cell therapy for myeloma patients.
Use Case
Type
Source
You might also like
BSH good practice paper on Diagnosis and management of monoclonal gammopathy of renal significance
The paper outlines a consensus approach to diagnosis, treatment and monitoring of MGRS, including guidance on the investigations required to confirm the condition, principles of supportive care, and haematological treatment strategies. It also highlights the need for ongoing multidisciplinary collaboration in managing this rare but clinically important disorder.
BSH GuidelineBSH/UKMS good practice paper on Advanced imaging for earlier diagnosis and morbidity prevention in myeloma
This Good Practice Paper from BSH/UKMS provides expert recommendations on the use of advanced imaging techniques, such as whole-body MRI and FDG-PET/CT, in the diagnosis and management of myeloma. It emphasises the importance of early detection of bone marrow disease to prevent complications and improve patient outcomes.
IMWG consensus definition of primary plasma cell leukemia based on peripheral blood plasma cell percentage
Explore the revised criteria for diagnosing primary plasma cell leukemia and its clinical implications.
IMWG Guideline
